Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
about
Multiple myelomaSmoldering multiple myeloma requiring treatment: time for a new definition?Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialSingle agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in IndiaLenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survivalBetter quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyImmunomodulatory drugs in multiple myeloma.Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature.Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agentsLenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaEarly versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97Lenalidomide and its role in the management of multiple myeloma.The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma.Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasoneTreatment of myeloma: cure vs controlTreatment of newly diagnosed myeloma.Initial therapy in multiple myeloma: investigating the new treatment paradigm.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesLenalidomide in multiple myeloma: current role and future directions.How best to use new therapies in multiple myeloma.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter?Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
P2860
Q24655964-32BB14AF-1441-4606-8555-EA4CE5847ECEQ26996579-DE8EE2A8-97AC-4C55-AF97-EB068E7A0669Q30433139-F0C44952-C774-4D7C-8CE5-1957D1216A65Q33389026-56F23BF2-C5FD-4647-A64A-FDED78D5D5CEQ33389111-B74DB8CE-512D-4A2D-88BD-93E8F5B06B16Q33398044-27B26108-22C1-44C6-A1CD-0B945CE3E756Q33424264-2D84F310-20B7-4204-BEE6-9A45E5F5ED5EQ33680252-77E01FA2-3667-4DF2-A652-344A276DB3A7Q33973877-9AFF3089-A932-4002-BD20-B9B1E7544F9AQ34011489-456FA0E8-4660-4A31-8A51-31BDAE497B4AQ34166574-F7243B62-061E-4437-879D-2FAEC0B1AAFFQ34213649-9104C8BB-BD51-4290-9EA9-EF3C48FB7CFDQ34325722-35972EDE-F342-46D5-B1D3-0539AA2DDB3CQ34436631-983457FE-5C30-407B-BE49-021CCEA871A7Q34451635-C63709BD-5417-4226-A276-14927B271FDAQ34541542-E8E4F846-C133-4F12-B34A-8943C1C3E8B6Q34604658-1C7002BF-F163-4FE1-B3A2-3BB7B3612CF8Q35172445-98481C7D-00C5-4D2D-BBED-ECAB64EB1515Q35685454-3870D266-5B98-4735-AE26-51CD2E12C886Q36765107-0342641C-BBFE-4DB2-B409-2BFAE99E62F8Q36915777-DDA940FE-181E-418E-A70E-358840C28E9EQ37088191-886B56C4-1AC1-4E9F-A2AF-4088FB82A17EQ37183439-BAD0844E-D97E-485C-8E25-4A21EE42E453Q37209935-9234F5AF-3D79-4028-9508-73441CADBD16Q37248327-35328539-ACFE-4AC2-B4BD-97BA21C4335DQ37268930-3AD930F7-8A1D-4DB8-AE82-AA430E13245CQ37284081-56E57697-4EDB-4E55-BF16-5579A52AD4FEQ37324251-88DDD4B1-1BC6-4F97-AA14-06FBF4855A28Q37411805-F457EA27-8915-46B6-9B99-9B1E5B24946CQ37454445-69AC39E1-5864-4D41-80AB-5580B5BA0D32Q37704401-8BB927AA-F83C-44D8-8D10-1F1AF4C3A392Q37723000-AE1AFD86-1C7B-4370-BBBF-4B857D17F013Q37761370-6A215B39-DCDD-4530-883B-742B05B5006FQ37842346-3FFA893C-0278-4F86-9EE3-4279D8BCACDFQ37851855-25B56543-FF57-4CF4-B67D-20207E60EF3AQ37980118-96B0ED66-4459-4D9C-9569-42297FDAB0DCQ37991783-858BA504-1C08-41A8-BE0B-C6280FEC9D60Q38031989-851542AE-31B8-4334-8A8E-4B0C425858F4Q38843235-B7F34B75-2133-411F-9585-22A922FC8DF6Q39065872-D7EE45CB-4A26-4EB0-852D-8243DA68022E
P2860
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Long-term results of response ...... ne in newly diagnosed myeloma.
@en
Long-term results of response ...... ne in newly diagnosed myeloma.
@nl
type
label
Long-term results of response ...... ne in newly diagnosed myeloma.
@en
Long-term results of response ...... ne in newly diagnosed myeloma.
@nl
prefLabel
Long-term results of response ...... ne in newly diagnosed myeloma.
@en
Long-term results of response ...... ne in newly diagnosed myeloma.
@nl
P2093
P50
P356
P1476
Long-term results of response ...... ne in newly diagnosed myeloma.
@en
P2093
A Keith Stewart
Brian Kabat
John A Lust
P Leif Bergsagel
Philip R Greipp
Shaji Kumar
Susan Geyer
Thomas E Witzig
P304
P356
10.4065/82.10.1179
P407
P50
P577
2007-10-01T00:00:00Z